科兴制药公告，近日，全资子公司深圳科兴药业有限公司收到国家药品监督管理局签发的《药物临床试 验批准通知书》，国家药监局批准同意深圳科兴自主研发的靶向BDCA2（血树突状细胞抗原2）的创新 药物"GB19注射液"开展临床试验。 ...

来源：经济观察网 经济观察网 根据截至2026年2月17日的公开信息，科兴生物（Sinovac Biotech Ltd.，美股代码：SVA） 作为一家在纳斯达克上市的疫苗企业，近期有以下几个值得关注的事件进展。需注意，科兴生物 （SVA）与A股科兴制药（688136）为独立上市公司。 股票近期走势 合同最新进展 2025年11月，科兴生物与巴西卫生部签署价值超7亿美元的疫苗供应合同，计划在未来10年内提供水痘 和狂犬疫苗。合同执行情况（如生产交付、收入确认）将是衡量公司海外业务复苏能力的关键指标。 以上内容基于公开资料整理，不构成投资建议。 公司结构与治理 与科兴生物控股层面相关的股东会议争议案庭审定于2026年4月下旬至5月初进行，涉及董事会职权归属 问题。该案结果可能间接影响上市公司治理结构，需关注其对公司运营稳定性的潜在波及。 科兴生物因未能在延长期限内提交2024年年度报告，于2025年11月收到纳斯达克退市决定函。公司表示 将申请听证会进行申辩，若未获批准，股票可能被暂停交易并退市。退市与否的最终决定是当前最受关 注的风险事件，其进展直接影响投资者对股票流动性和公司治理稳定性的预期。 ...

Group 1: Core Insights - UBS's in-depth research in China identifies two main industry themes for 2026: self-sufficiency and overseas expansion [1] - The research covered various sectors including technology, industrial, healthcare, consumer, and utilities, visiting over 100 companies and industry experts [1] - The report highlights a shift in investor interest, with capital goods, media entertainment, and real estate development seeing increased research focus, while semiconductor and automotive parts sectors experienced a decline [1] Group 2: Technology Sector Insights - The technology sector is a key focus, with advancements in self-sufficiency moving from isolated breakthroughs to industry-wide collaboration [2] - AI capital expenditure is expected to grow steadily in 2026, driven by strong demand for AI applications and local semiconductor production [3] - Despite uncertainties regarding H200 GPU imports, domestic supply chains are adapting through technology substitution and demand upgrades [3] Group 3: Semiconductor Developments - The localization of China's semiconductor industry is accelerating, with significant progress in advanced etching/ deposition equipment, advanced packaging, and high-end analog chips [4] - Capital expenditure for wafer fabrication equipment (WFE) is projected to grow by 10-15% annually, driven by capacity expansion in advanced logic and memory wafer fabs [4] - Domestic manufacturers anticipate a substantial increase in storage capital expenditure in 2026, aligning with a global upcycle in the storage industry [4] Group 4: Overseas Expansion Trends - Multiple industries, including industrial, biopharmaceuticals, and consumer goods, are focusing on overseas expansion as a key growth strategy [6] - In the industrial sector, overseas orders for AIDC and renewable energy storage equipment are increasing significantly [7] - The healthcare sector is also prioritizing global expansion, with biopharmaceutical companies actively pursuing international collaborations and local sales team development [9] Group 5: Key Recommendations - UBS recommends several core stocks in the technology and semiconductor sectors, including Northern Huachuang (advanced etching/ deposition), Changdian Technology (advanced packaging), and Horizon Robotics (edge AI) [5][12] - In the healthcare sector, companies like WuXi AppTec (CRO/CDMO) and 3SBio (biopharmaceuticals) are highlighted as key beneficiaries of global expansion [12] - The consumer sector sees recommendations for Jason Furniture (overseas expansion) and Leap Motor (new energy vehicles), while Gree Electric Appliances is advised to sell due to margin pressures [12] Group 6: Overall Industry Outlook - The report concludes that China's industrial development in 2026 will be characterized by a dual focus on self-sufficiency in technology and overseas expansion in various sectors [13] - The integration of these two themes is expected to enhance China's economic globalization, with technology supporting overseas expansion and vice versa [13] - Investment opportunities are identified in sectors with low crowding and improving fundamentals, as well as in high-growth areas like AI and semiconductors [13]

产品研发进展 经济观察网 科兴生物制药股份有限公司近期在H股上市进程、创新药管线关键进展及海外市场拓展等方 面有动态更新。 高管变动 科兴制药于2025年11月向港交所主板提交H股上市申请，后续需关注港交所的审核进展、聆讯时间及最 终上市时间表。若成功上市，将拓宽公司资本通道，支持国际化战略。 公司结构与治理 股东会议争议案庭审定于2026年4月下旬至5月初进行，涉及董事会职权归属，可能影响公司治理稳定 性。此事件关联科兴生物控股层面，可能间接波及上市公司。 以上内容基于公开资料整理，不构成投资建议。 GB18注射液（GDF15单抗）针对肿瘤恶病质的国内I期临床试验于2025年10月启动入组，未来将公布安 全性、耐受性及药代动力学数据，并可能推进至后续临床阶段。该药是潜在"First-in-Class"药物，瞄准 全球未满足临床需求。其他核心管线包括聚焦炎症性肠病的GB24（TL1A/LIGHT双靶点）、针对系统 性红斑狼疮的GB19，以及三抗药物GB26，均处于早期临床阶段，未来需关注其临床试验结果与国际化 申报进展。 海外市场拓展 白蛋白紫杉醇等产品已在欧盟、阿根廷、秘鲁等多国获批，2026年将继续在拉美 ...

Core Viewpoint - The recent surge in "A+H" listings has seen over 100 A-share companies at various stages of seeking listings in Hong Kong, with a notable presence of biopharmaceutical companies like Kexing Pharmaceutical, which has submitted its application for dual listing [1][2]. Company Overview - Kexing Pharmaceutical, established in 1989 and restructured into a joint-stock company in 2019, is headquartered in Jinan, Shandong [4][3]. - The actual controller of the company, Deng Xueqin, holds 56.27% of the voting rights as of October 2025 [5]. - The board of directors consists of eight members, including four executive directors [6]. Financial Performance - Kexing Pharmaceutical's revenue has fluctuated in recent years, with figures of 1.31 billion, 1.26 billion, 1.40 billion, and 700 million RMB reported for 2022, 2023, 2024, and the first half of 2025, respectively [25]. - The company achieved profitability in 2024, with net profits of 27.05 million RMB and 78.96 million RMB in the first half of 2025 [26]. - Sales expenses have been high, totaling 2.369 billion RMB over three and a half years, while R&D expenses were approximately 788 million RMB, accounting for 16.8% of total revenue [27]. Product Portfolio - Kexing Pharmaceutical has established a product matrix consisting of commercialized products, a research pipeline, and introduced products [9][12]. - The company has four main commercialized products, including SINOGEN, which holds a 55.2% market share in China's short-acting interferon α1b market [10][11]. - The revenue from these products for the years 2022, 2023, 2024, and the first half of 2025 was 1.314 billion, 1.254 billion, 1.392 billion, and 680 million RMB, respectively [12]. Research and Development - Kexing Pharmaceutical has a pipeline of 5 products in clinical stages and 10 in preclinical stages, focusing on oncology, autoimmune diseases, and degenerative diseases [13][18]. - The company has developed a "3KX technology platform" to enhance the R&D process, integrating various advanced technologies [14]. - The most advanced products in the pipeline are GB05 and GB-K02, both currently in Phase III clinical trials [19][20]. Market Position and Challenges - The company is facing challenges due to a lack of blockbuster products and a relatively weak R&D capability compared to other biotech firms [30]. - The sales team may struggle with centralized management due to a dispersed pipeline layout, leading to higher sales expenses [30].

Market Overview - The biopharmaceutical sector increased by 0.65% on February 4, with Weiguang Bio leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Individual Stock Performance - Weiguang Bio (002880) closed at 30.72, up 7.79% with a trading volume of 106,600 shares and a transaction value of 320 million yuan [1] - Kanglaweishi (920575) closed at 11.07, up 5.63% with a trading volume of 105,200 shares and a transaction value of 114 million yuan [1] - Kangchen Pharmaceutical (603590) closed at 41.61, up 5.61% with a trading volume of 50,700 shares and a transaction value of 208 million yuan [1] - Other notable performers include Zhifei Biological (300122) up 2.61%, Kanghong Pharmaceutical (002773) up 2.31%, and Watson Bio (300142) up 1.92% [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 159 million yuan from institutional investors, while retail investors saw a net inflow of 187 million yuan [2] - The overall retail investor net outflow was 28.35 million yuan [2] Detailed Capital Flow for Selected Stocks - Wanze Co. (000534) had a net inflow of 67.22 million yuan from institutional investors, while retail investors experienced a net outflow of 99.26 million yuan [3] - Kangtai Biological (300601) saw a net inflow of 15.17 million yuan from institutional investors, with retail investors also experiencing a net outflow [3] - Shanghai Laisai (002252) had a net inflow of 14.01 million yuan from institutional investors, while retail investors faced a net outflow [3]

Economic Growth and Development - The GDP of Zhangqiu District is projected to grow by 5.9% in 2025, with general public budget revenue expected to reach 6.32 billion yuan, an increase of 3.2% [1] - Per capita disposable income for urban and rural residents is anticipated to rise by 4% and 5.5% respectively [1] - Zhangqiu District has been recognized as one of the top 100 districts in terms of comprehensive strength (ranked 58th) and tourism competitiveness (ranked 97th) in China [1] Consumption and Trade - The district is focusing on economic stability and growth, with a series of 55 consumption activities expected to generate 1.81 billion yuan in consumer spending [1] - The total retail sales of social consumer goods are projected to reach 36.39 billion yuan, reflecting a growth of 12.3% [1] - The foreign trade market is expanding, with 96 new import and export enterprises and 15 cross-border e-commerce companies established, achieving a total import and export value of 9.94 billion yuan, an increase of 23% [1] Project Development and Investment - There are currently 608 ongoing projects, with all 175 key provincial and municipal projects under construction [2] - Key provincial projects, including Shandong University Longshan Campus and Aerospace Information University, have completed investments of 7.35 billion yuan, achieving an investment completion rate of 119% [2] - The district has signed 76 new projects, including significant investments in the automotive industry, and has ranked first in the city for the number of signed projects exceeding 100 million yuan [2]

一、回购股份的基本情况 证券代码：688136 证券简称：科兴制药 公告编号：2026-010 科兴生物制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/19 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2025 3 3 | 17 | 日~2026 | 年 | 16 | 日 | | 预计回购金额 | 3,000万元~6,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | 累计已回购股数 | □为维护公司价值及股东权益 1,319,333股 | | | | | | | 累计已回购股数占总股本比例 | 0.66% | | | | | | | 累计已回购金额 | 4,924.18万元 | | | | | | | 实 ...

近日，科兴制药发布公告称，预计2025年年度实现归母净利润为1.35亿元至1.75亿元，同比增加 328.83%至455.89%，预计归母净利润扣除非经常性损益后为5000万元至7000万元，同比增加41.83%至 98.56%。 (编辑：杨燕 林辰)关键字： 医疗 （科兴制药公告） 本期业绩变化的主要原因是公司积极开拓海外市场，实现了海外收入的强劲增长，推动营业收入持续增 长。报告期内，非经常性损益金额较上年同期变动主要系公司持有的私募基金公允价值变动及处置下属 子公司所致。 ...

Core Viewpoint - Company Kexing Pharmaceutical (科兴制药) is expected to achieve a net profit of approximately 135 million to 175 million yuan in 2025, representing a year-on-year increase of 328.83% to 455.89% compared to the previous year, driven by its "innovation + internationalization" strategy [1] Group 1: Financial Performance - The projected net profit for 2025 is estimated to be between 135 million and 175 million yuan, an increase of 103.52 million to 143.52 million yuan from the previous year [1] Group 2: Strategic Focus - Kexing Pharmaceutical has differentiated its innovation drug pipeline by focusing on three key areas: oncology, autoimmune diseases, and metabolic diseases, which collectively account for 32.2% of the global pharmaceutical market and show significant growth potential [2] - The oncology drug market is expected to grow from 253.3 billion USD in 2024 to 419.8 billion USD by 2030, with a compound annual growth rate of 8.8% [2] Group 3: Product Development - The GB18 injection, targeting GDF-15, is advancing to fill a significant market gap in treating cancer cachexia, with clinical trial approvals from both the FDA and the National Medical Products Administration [2] - Kexing is also developing innovative pipelines for autoimmune diseases, including the GB24 project targeting dual pathways for inflammatory bowel disease and the GB19 project for systemic lupus erythematosus [3] Group 4: AI Integration - In March 2025, Kexing Pharmaceutical entered a strategic partnership with Baidu Biotechnology to leverage AI technology in the development of large molecule drugs for oncology and autoimmune diseases [3] Group 5: International Expansion - Kexing has established a comprehensive global market network covering around 70 countries, with significant sales performance of its core products, including EPOSINO, which leads the market in export volume among similar products [4] - The company has successfully registered and commercialized multiple biopharmaceuticals in Southeast Asia, Latin America, and the Middle East, demonstrating its robust internationalization efforts [4]